Oncology Central

KEYTRUDA® scores big again in NSCLC Phase III KEYNOTE-189 study

0
Details of the KEYNOTE-189 study have been announced by Merck (known as MSD outside the United States and Canada).

The results demonstrate that its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), significantly improves overall survival (OS) in combination with pemetrexed (ALIMTA®) and cisplatin or carboplatin for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC), reducing the risk of death by half compared with chemotherapy alone.

To view restricted content, please:
Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.